Ann Monardo, DO
Gastroenterology · Bowling Green, KYNPI 1053832311
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 321 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by AbbVie at 27.2% of the total. 2025 is the largest year on record at $2,142, 7.8 times the $273 reported in 2019.
Across 321 payments — averaging $25.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$1K
- Regeneron Healthcare Solutions, Inc.$620
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$550
- Janssen Scientific Affairs, LLC$423
- Gilead$340
- plus $3K from 28 others
What the payments were for
- Food & beverage$7,90496%
- Education$3004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 104 | $2,233 |
| Johnson & Johnson | 35 | $1,065 |
| Regeneron Healthcare Solutions, Inc. | 16 | $620 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 29 | $550 |
| Janssen Scientific Affairs, LLC | 5 | $423 |
| Gilead | 14 | $340 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $329 |
| Ambu Inc. | 2 | $260 |
| E.r. Squibb & Sons, L.L.C. | 2 | $237 |
| Ardelyx, Inc. | 12 | $233 |
| QOL Medical, LLC | 11 | $229 |
| Intercept Pharmaceuticals, Inc. | 6 | $194 |
| Phathom Pharmaceuticals, Inc. | 10 | $182 |
| Sanofi | 6 | $152 |
| Cook Medical LLC | 6 | $151 |
| Mallinckrodt Hospital Products Inc. | 1 | $147 |
| Lilly USA, LLC | 7 | $125 |
| Madrigal Pharmaceuticals | 6 | $119 |
| Ironwood Pharmaceuticals, Inc | 6 | $98 |
| Medtronic | 5 | $96 |
| Pfizer | 3 | $79 |
| Aimmune Therapeutics, Inc. | 3 | $77 |
| AstraZeneca | 2 | $50 |
| Braintree Laboratories, Inc. | 2 | $35 |
| Bristol Myers Squibb | 2 | $30 |
| Organon | 2 | $25 |
| Novo Nordisk | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Olympus America Inc. | 1 | $16 |
| Amgen | 1 | $14 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $13 |
| Ipsen Biopharmaceuticals, Inc | 1 | $13 |
| Merck | 1 | $13 |
| Boston Scientific | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,204 in reported general payments places this provider in the 75th percentile of 207 gastroenterology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 23 | $68,781 |
| CreonLipase/Protease/Amylase | 25 | $39,667 |
| LinzessLinaclotide | 14 | $10,501 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 126 | $8,506 |
| Mesalamine | 19 | $3,936 |
| Pantoprazole Sodium | 152 | $1,905 |
| Famotidine | 70 | $720 |
| Sucralfate | 14 | $522 |
| Omeprazole | 68 | $520 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 28 | $422 |
| Esomeprazole Magnesium | 11 | $413 |
| Dicyclomine Hcl | 16 | $324 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $550 | $68,78123 claims |
| AbbVieCreon, Linzess | $2,233 | $50,16839 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 207 gastroenterology providers in Kentucky.
Other gastroenterology in Bowling Green
- Avinash AravantagiBowling Green$45K
- Cory FieldingBowling Green$14K
- Gerald DrydenLouisville$2.1M
- Zahid SaeedCrestview Hills$442K
- Matthew CaveLouisville$340K
- Michael KreaseLouisville$322K
- Sunana SohiLouisville$220K
- Jeffrey TuvlinLouisville$202K
- Stephen McClaveLouisville$124K
- Uday ShankarHazard$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.